ODAC Votes in Favor of Olaparib as a First-Line Maintenance Therapy in Metastatic Pancreatic Cancer

The PARP inhibitor was recommended as a first-line maintenance monotherapy for patients with germline BRCA-mutated metastatic pancreatic cancer.

Source: CancerNetwork - December 18, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news